Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received a consensus recommendation of “Hold” from the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $4.79.

A number of analysts recently weighed in on MRNS shares. StockNews.com started coverage on shares of Marinus Pharmaceuticals in a research note on Thursday. They set a “sell” rating for the company. Royal Bank of Canada decreased their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of large investors have recently made changes to their positions in MRNS. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $727,000. Squarepoint Ops LLC purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $206,000. AQR Capital Management LLC increased its holdings in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $64,000. Finally, Assenagon Asset Management S.A. increased its holdings in Marinus Pharmaceuticals by 70.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock valued at $782,000 after acquiring an additional 183,396 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $0.55 on Friday. The stock has a market cap of $30.29 million, a P/E ratio of -0.22 and a beta of 1.03. The firm has a fifty day moving average price of $0.43 and a 200 day moving average price of $0.92. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.